RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
Updated CSA Technical Guide for Infrastructure in Permafrost published
A second updated edition of the CSA national permafrost standard was published on May 21, 2019 and features climate and climate change information provided by…
RSI chairs panel session at Building the Next Generation of Canadian Infrastructure Conference
RSI chairs and presents on panel sessions for the Toronto conference, “Building the Next Generation of Canadian Infrastructure: Defining a roadmap for optimizing infrastructure planning,…
RSI Chairs Joint FAO/WHO Expert Meeting on Microbiological Risk Assessment (JEMRA)
RSI’s Dr. Emma Hartnett chaired the recent Joint FAO/WHO Expert Meeting on Microbiological Risk Assessment (JEMRA). The focus of the week-long event held March 11…
RSI partners with Engineers Canada to offer Online Workshop on the PIEVC Protocol
RSI and Engineers Canada are partnering to offer an online version of the introductory workshop on the PIEVC Protocol for infrastructure climate risk and vulnerability…